

Article

The emergence of SARS-CoV-2 within the dog population in Croatia: host factors and clinical outcome

Vladimir Stevanovic (VLS)^{1,2*}, Irena Tabain (IT)^{3*}, Tatjana Vilibic-Cavlek (TVC)^{3,4*}, Maja Mauric Maljkovic⁵, Iva Benvin^{1,2}, Zeljka Hruskar³, Snjezana Kovac¹, Iva Smit², Gorana Miletic¹, Suzana Hadina², Vilim Staresina¹, Lada Radin², Valentina Plichta², Branimir Skrlin², Zoran Vrbanc², Mirna Brkljacic², Marija Cvetnic², Josipa Habus², Kresimir Martinkovic², Iva Zecevic², Gabrijela Jurkic², Ivana Ferencak³, Zinka Stritof², Matko Perharic², Lovro Bucic⁶, Ljubo Barbic^{1,2}

¹Department of Microbiology and Infectious Diseases with Clinic, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia

²Veterinary Teaching Hospital, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia

³Department of Virology, Croatian Institute of Public Health, Rockefellerova 7, 10000 Zagreb, Croatia

⁴School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia

⁵Department for Animal Breeding and Livestock Production, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia

⁶Department of Epidemiology, Croatian Institute of Public Health, Rockefellerova 7, 10000 Zagreb, Croatia

* Correspondence: VLS: vladimir.stevanovic@vef.hr, Tel.: +385 1 2390 214, IT: irena.tabain@hzjz.hr, Tel.: +385 1 48 63 295, TVC: tatjana.vilibic-cavlek@hzjz.hr, Tel.: +385 1 48 63 238

Abstract:

Over a year into the COVID-19 pandemic, there is growing evidence that SARS-CoV-2 infections among dogs are more common than previously thought. In this study, the prevalence of SARS-CoV-2 antibodies was investigated in two dog population. The first group was comprised of 1069 dogs admitted to the Veterinary Teaching Hospital for any given reason. The second group included dogs that shared households with confirmed COVID-19 cases in humans. This study group numbered 78 dogs. In COVID-19 infected households, 43.9% tested ELISA positive, and neutralisation antibodies were detected in 25.64% of dogs. Those data are comparable with the secondary attack rate in the human population. With 14.69% of dogs in the general population testing ELISA positive, there was a surge of SARS-CoV-2 infections within the dog population amid the second wave of the pandemic. Noticeably seroprevalence of SARS-CoV-2 in the dog and the human population did not differ at the end of the study period. Male sex, breed and age were identified as significant risk factors. This study gives strong evidence that while acute dog infections are mostly asymptomatic, they can pose a significant risk to dog health. Seropositive dogs had a 1.97 times greater risk for developing central nervous symptoms.

Keywords: SARS-CoV-2, animals, dogs, epidemiology, risk factors, clinical picture, Croatia

1. Introduction

Animal origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been hypothesised since the beginning of the coronavirus disease (COVID-19) pandemic [1]. Under experimental conditions, SARS-CoV-2 has a broad range of susceptible animal hosts [2,3]. Due to close contact with owners, pet animals were assumed to be at increased risk of infection in natural conditions. As opposed to the results of experimental infections [4], early studies showed that in natural settings probability of dogs getting infected is the same or higher than in cats [5-8].

There is currently no evidence that dogs have a significant role in the virus spreading. On the other hand, the rising number of confirmed infections in dogs raises questions regarding the clinical consequences because the clinical spectrum of COVID-19 in humans is still updated. An additional concern is rising over post-acute COVID-19 syndrome with a long-lasting effect on health [9].

This study aimed to examine the prevalence of SARS-CoV-2 infection in the Croatian dog population and host factors predisposing to infection. The study was conducted in two populations, dogs from COVID-19 infected households and those admitted to the Veterinary Teaching Hospital. Two serological tests were used, and their sensitivity and specificity determined. The medical history and clinical presentation data were analysed to address the potential clinical manifestation of SARS-CoV-2 infections in dogs.

2. Materials and Methods

On 18 December 2020, dog owners diagnosed with COVID-19 were invited to join this study. Only owners with positive RT-PCR test could enter the study. After signing the consent, signalment, dog medical history and blood samples were taken. Obtained serum samples were stored at -80 °C until testing. A total of 78 dogs were part of this study

From 1 July till 31 December 2020, remaining dog serum samples were collected. Dogs were sampled during their healthcare visits at Veterinary Teaching Hospital at the Faculty of Veterinary Medicine, University of Zagreb, Croatia (Veterinary Hospital). To be included in this study, signalment data such as breed, sex, age and place of residence had to be available. For statistical analysis, medical history data were collected as well. In total, 1069 dog serum samples and their data were included in the study. In the following text, those dogs are referred to as the general population.

A total of 169 serum samples collected during 2018 and 2019 were used as the negative control. The general population was represented with an age-stratified panel of 104 serum samples. Additionally, 65 randomly selected samples of dogs from breeding colonies were included. All control samples were pretested for the canine respiratory coronavirus (CRCoV) antibodies. For 40 samples, canine coronavirus (CCoV) antibody status was known as well.

Medical records of 1000 randomly selected dogs admitted to University Hospital from 1 July till 31 December 2019 were retrieved. The inclusion criterion was that dogs were blood sampled during a veterinary visit.

A sampling of animals and retrieving medical data for this study was approved by the Ethics Committee of the Faculty of Veterinary Medicine, the University of Zagreb, Croatia (decision number: 640-01/20-02/12).

Detection of SARS-CoV-2 antibodies was performed by an indirect enzyme-linked immunosorbent assay (ELISA). Each serum sample was tested in two wells, one coated with receptor-binding domain protein (RBD) solution and the other with phosphate-buffered saline (PBS) to avoid false-positive results due to serum-specific background noise [10]. Designated wells of ELISA plate (Nunc MaxiSorp, Thermo Fisher Scientific, Waltham, Massachusetts) were coated with 100 ng of RBD (Sino Biological, Beijing, China) diluted in 50 µl of PBS or the same volume of PBS. Following overnight incubation, the plate was washed twice with 300 µl of PBS per well using an automatic ELISA plate washer (Tecan, Männedorf, Switzerland). Blocking was done by adding 200 µl of 3% bovine serum albumins (St. Louis, Missouri) and 0.5% (v/v) Tween 20 (Santa Cruz Biotechnology, Santa Cruz, California) in PBS in all wells and incubation for 2 hours at 37 °C.

Subsequently, wells were washed three times with 300 µl of washing buffer made of PBS and 0.5% Tween 20. Serum samples diluted in blocking buffer (1:100) were added in one RBD coated well and one well coated with PBS, in the volume of 100 µl. After one hour of incubation at room temperature, the plate was washed five times. Horseradish peroxidase-conjugated goat anti-dog IgG antibodies (Jackson ImmunoResearch Europe, Ely, United Kingdom) were diluted 1:65000 in blocking buffer and added 100 µl per well. After one hour at room temperature, the plate was washed five times. In the next step, 100 µl of tetramethylbenzidine substrate (TMB High Sensitivity ELISA substrate) (Abcam, Cambridge, United Kingdom) per well was added. After 15 minutes of incubation in the dark, the reaction was stopped by adding the same volume of 1M H₂SO₄ (Kemika, Zagreb, Croatia). Optical density (OD) was read on the microplate reader (Tecan, Männedorf, Switzerland) at 450 nm. Corrected OD for each sample was calculated as a difference of OD between RBD coated and non-coated well. The initial cut-off value was calculated by adding three standard deviations to the arithmetic mean of corrected OD values of 169 control samples. Samples were regarded as positive if corrected OD > 0.203. In subsequent runs, every plate had positive, negative and cut-off control included.

The microneutralisation test has been described previously [6]. In brief, serial two-fold dilutions of serum samples were prepared in wells of a 96-well microneutralisation plate. Each dilution was tested in duplicate, mixing 25 µl of serum dilution and the same volume of SARS-CoV-2 virus containing 100 TCID₅₀ viral particles. The results' repeatability was ensured by virus back titration and low titer positive and negative dog serum samples included in each run. After one hour of incubation at 37°C with CO₂, 50 µl of 2x10⁵ E6 Vero cells/ml were added to each well. Antibody titre was the reciprocal of the highest dilution of the serum that showed 100% neutralisation after four days of incubation. MNT procedure was carried out in the biosecurity level 3 laboratory. Ten known CCoV and CRCoV positive pre-pandemic serum samples were tested to assess MNT specificity. Due to some samples' cytotoxicity, a serum was defined as MNT positive if the antibody titer was 1:8 or more.

Descriptive statistics are presented as numbers and percentages. All statistical analysis was performed using R 4.0.5. Seroprevalence rates and exact 95% confidence intervals (95%CI) were calculated using epiR. Obtained data were analysed using the two-tailed χ^2 test or Fishers' exact test, and p values below 0.05 were considered statistically significant. Odds ratio (OR) of bivariate risk factors, risk ratio (RR), and 95% CI were calculated using epitools. Logistic regression analysis was used to calculate OR of multinomial risk factors and assess interactions between risk factors. When evaluating for interactions between risk factors, the multivariable logistic regression model was selected through the Akaike information criterion. The logit link in glm was used, and NA (not available) were excluded from the model. In the variable breed clades, complete separation occurred, so the Firth correction was applied using logistf. Association between ELISA and MNT was determined with Cohen's kappa coefficient (κ) calculated using irr.

3. Results

- **Methods and seroprevalence**

Pre-pandemic samples were tested to exclude potential cross-reactivity of SARS-CoV-2 antigens and antibodies against CCoV (alphacoronavirus) and CRCoV (betacoronavirus). In the control group, 41.3% (n = 104) were positive for CRCoV, and 27 samples were known positive for CCoV antibodies, but none of the pre-pandemic samples tested ELISA positive. The same was true for the neutralisation assay. In COVID-19 positive households, ELISA reactivity was detected in 43.9%, and neutralisation antibodies were detected in 25.64% of dogs (n = 78). There was a substantial agreement of methods with a kappa value of 0.62 (95% CI 0.45 - 0.75). In the general population, 157 (14.69%, n = 1069)

samples were ELISA positive, and those samples were MNT tested. For eight sera, there was not enough remaining volume. Out of 149 ELISA positive samples, 23 had neutralisation activity.

The positivity rate of ELISA tested samples varied significantly, with the lowest prevalence in July ($n = 126$, 7.14%, 95% CI 3.32 – 13.13) and highest in September ($n = 233$, 19.74%, 95% CI 14.83 – 25.44) (Table 1., Figure 1.). Out of 23 ELISA positive samples which showed neutralisation activity, 16 were collected in December ($n = 149$, Fisher's exact test $p < 0.0001$).

Table 1. Monthly seroprevalence rate in dogs admitted to the Veterinary Teaching Hospital from 1 July to 31 December 2020.

| | Number of tested samples | ELISA ^a positive N (%) | Seroprevalence 95% CI ^b (%) | OR ^c | OR ^c 95% CI | P |
|------------------|--------------------------------|---|---|-----------------|---------------------------|--------|
| July | 126 | 9 (7.14) | 3.32 – 13.13 | 0.08 | 0.04 – 0.14 | - |
| August | 152 | 23 (15.13) | 9.84 – 21.83 | 2.32 | 1.06 – 5.47 | 0.042 |
| September | 233 | 46 (19.74) | 14.83 – 25.44 | 3.2 | 1.58 – 7.2 | 0.002* |
| October | 191 | 24 (12.57) | 8.22 – 18.12 | 1.87 | 0.86 – 4.38 | 0.126 |
| November | 200 | 24 (12) | 7.84 – 17.33 | 1.77 | 0.82 – 4.15 | 0.161 |
| December | 167 | 31 (18.56) | 12.97 – 25.3 | 2.96 | 1.41 – 6.84 | 0.006* |

Note: Logistic regression was used to calculate the odds ratio with the July rate as the reference category. ^aELISA – enzyme-linked immunoassay, ^bCI – confidence interval, ^cOR – odds ratio, * – statistically significant




Figure 1. The weekly number of SARS-CoV-2 seropositive dogs and new q-RT PCR human cases in Zagreb from 1 July and 31 December 2020. The number of seropositive dogs is represented as a percentage of tested samples (red) and a two-week moving average trend line (red). Error bars are representing a 95% confidence interval. The number of new human SARS-CoV-2 infections in Zareb is publicly available (<https://www.koronavirus.hr>) and here is represented as a two-week moving average trend line in black.

• Predisposing factors

Living in COVID-19 positive households was a significant risk factor for seroconversion. The odds of testing ELISA positive were 4.49 ($n = 1147$, OR 95% CI 2.78 - 7.24, $p < 0.0001$) times higher for dogs in infected households than dogs in the general population.

In other words, dogs from COVID-19 infected households had a 2.97 times greater risk of infection than in the general population ($n = 1147$, RR 95% CI 2.22 – 3.97, $p < 0.0001$). In positive households, ELISA positive dogs were 7.83 ($n = 183$, OR 95% CI 3.46 – 17.68 $p < 0.0001$) times more likely to test MNT positive than in the general population.

On the other hand, living in animal shelters was not a significant risk factor. The rate of ELISA positivity was similar in the general population between privately owned and dogs from shelters ($n = 1065$, OR = 1.03, 95% CI 0.35 – 3.01, $p = 1$).

Another important predisposing factor was sex. In dogs from COVID-19 positive households, female dogs were overrepresented with 63.63% ($n = 77$). Male dogs tested were more often ELISA positive, but the difference did not mount to the level of statistical significance ($n = 77$, OR = 1.16, 95% CI 0.45 – 2.94, $p = 0.76$). MNT results were similar, with 28.57% male testing positive compared to 24.49% female animals ($n = 77$, OR = 1.23, 95% CI 0.43 – 3.51, $p = 0.69$). In the general population, the female to male ratio was more even. Male dogs were 1.6 times more likely to be ELISA positive than female ($n = 1069$, OR = 1.6, 95% CI 1.13–2.27 $p = 0.008$). Results of the MNT testing were not influenced by sex ($n = 149$, OR = 1.45, 95% CI 0.56 – 3.79, $p = 0.44$).

The age of dogs was from few months up to 15 years in positive households and 18 years in the general population. Among dogs from COVID-19 infected households lowest seroprevalence was recorded in dogs under one year of age, with a significantly increased positivity rate in dogs aged between one and five years ($n = 75$, OR = 10.5, 95% CI 1.44 – 27.82, $p = 0.04$). In this group, the number of dogs with neutralising antibodies did not significantly differ between age groups (Supplementary Table S1.). In the general population, dogs aged five and six years were most likely to test ELISA positive ($n = 1069$, OR = 1.67, 95% CI 1.02 – 2.17 $p = 0.038$) (Supplementary Figure S1.). When age distribution in the general population was compared between male and female dogs, odds of male dogs between four and seven years of age to test ELISA positive were 2.11 ($n=555$, OR = 2.11, 95% CI 1.25–3.54, $p = 0.0048$) times greater than males of any other age and 3.82 ($n = 171$, OR = 3.82 95% CI 1.56 – 9.39, $p = 0.0034$) times greater than females same age.

Among dogs from COVID-19 infected households, 29 breeds and a mixed-breed group were represented, and in the general population, 89 breeds and a mixed-breed group were represented. In dogs from COVID-19 infected households, the sample size was too small to address breed predisposition to SARS-CoV-2 infection further. In the general population, a small number of animals represented many breeds, so purebred dogs were further grouped into the clades based on their phylogenetic relationship [11]. When assessing breed clades, with the mixed breed as the reference category, only the Continental Herders stood out significantly different (OR = 4.63 95% CI 1.94–11.03 $p = 0.0005$) (Supplementary Table S2.). Belgian Shepherds only represented this clade with a 3.19 time greater risk of testing ELISA positive than any other breed ($n = 707$, RR 95%CI 1.84 – 5.51, $p < 0.001$). Upper respiratory system disorders have been associated with the brachycephalic skull conformation [12,13]. Brachycephalic dogs did not test more ELISA positive ($n = 739$, OR = 1.02, 95% CI 0.66 – 1.58, $p = 0.94$) or MNT positive ($n = 95$, OR = 0.56, 95% CI 0.14 – 2.22, $p = 0.53$).

• Clinical manifestation

Dog owners from COVID positive households did not notice any apparent change in their pets' health. In the general population, clinical information was retrieved from their medical records and validated by the clinicians.

Based on the anamnesis, initial presentation, physical examination and X-ray, dogs were classified into two large groups: animals with signs of respiratory system involvement and animals with signs of digestive system involvement, regardless of the underlying condition. Neither animals with respiratory ($n = 728$, OR = 0.62, 95% CI 0.37 – 1.04, $p = 0.07$) nor animals with gastrointestinal symptoms ($n = 1036$, OR = 0.87, 95% CI 0.56 – 1.35, $p = 0.53$) were more likely ELISA positive. The clinical manifestations were further classified into acute respiratory or gastrointestinal disorders, chronic respiratory or gastrointestinal disorders, central nervous system (CNS), ophthalmic conditions, dermatologic disorders, heart disorders, malignancies, endocrine disorders, surgical cases, general health check, nonspecific signs of early infection, and other disorders. The last group included disorders recorded in only a few cases like acute renal failure, cystitis or hydrocephalus. CNS symptoms included impaired consciousness to the level of stupor or coma, seizures, cranial nerve deficits, vestibular and cerebellar ataxia. CNS disorders attributed to disease of other organ systems, e.g. otitis or trauma, neoplasia and malformation, were excluded from this group. There was insufficient data to be classified for 112 dogs, and they were excluded from this analysis. The OR for the CNS symptom group was 2.14 ($n = 957$, OR 95% CI 1.06 – 4.17, $p = 0.03$) than the rest of the analysed population. ELISA positive dogs had 1.97 times greater risk for developing CNS symptoms than ELISA negative ($n = 957$, RR 95% CI 1.19-3.04, $p = 0.01$). There was no significant increase in the number of ELISA positive dogs in other groups (Table 2.).

Table 2. Association of the serological status on clinical presentation at the Veterinary Teaching Hospital.

| Diagnosis | Number of tested samples | Number of ELISA ^a positive samples (%) | Seroprevalence 95% CI ^b | OR ^c | OR 95%CI | P |
|-------------------------|--------------------------|---|------------------------------------|-----------------|-------------|-------|
| Surgical | 269 | 37 (13.75) | 9.87 – 18.46 | 0.16 | 0.11 – 0.22 | - |
| Acute GI ^d | 146 | 23 (15.75) | 10.26 – 22.69 | 1.17 | 0.66 – 2.05 | 0.58 |
| Acute respiratory | 48 | 8 (16.67) | 7.48 – 30.22 | 1.25 | 0.51 – 2.77 | 0.6 |
| Cardio | 57 | 8 (14.04) | 6.26 – 25.79 | 1.02 | 0.42 – 2.23 | 0.96 |
| Chronic GI ^d | 27 | 4 (14.81) | 4.19 – 33.73 | 1.09 | 0.31 – 3.03 | 0.88 |
| Chronic respiratory | 14 | 1 (7.14) | 0.18 – 33.87 | 0.48 | 0.03 – 2.53 | 0.49 |
| CNS ^e | 59 | 15 (25.42) | 14.98 – 38.44 | 2.14 | 1.06 – 4.17 | 0.03* |
| Dermatologic | 77 | 12 (15.58) | 8.32 – 25.64 | 1.16 | 0.55 – 2.29 | 0.68 |
| Early infection | 31 | 6 (19.35) | 7.45 – 37.47 | 1.5 | 0.53 – 3.71 | 0.40 |
| Endocrine | 18 | 1 (5.56) | 0.14 – 27.29 | 0.37 | 0.02 – 1.88 | 0.34 |
| Healthy | 28 | 4 (14.29) | 4.03 – 32.67 | 1.05 | 0.3 – 2.9 | 0.94 |
| Malignancy | 70 | 7 (10) | 4.12-19-52 | 0.7 | 0.27 – 1.55 | 0.41 |
| Ophthalmic | 18 | 1 (5.56) | 0.14 – 27.29 | 0.37 | 0.02 – 1.88 | 0.34 |
| Other | 95 | 8 (8.42) | 3.71 – 15.92 | 0.58 | 0.24 – 1.23 | 0.18 |

Note: The most numerous category "Surgical" was used as a reference category in logistic regression analysis. ^aELISA – enzyme-linked immunoassay, ^bCI – confidence interval, ^cOR – odds ratio, ^dGI – gastrointestinal, ^eCNS – central nervous system

A multivariable logistic regression model was used when assessing for interactions between dog age, sex, and CNS symptoms. Interaction between dog age and sex, sex and CNS symptoms and age, gender and CNS symptoms were not significant and were not

implemented in the model. The interaction between age and CNS was significant at 6 and 11 years (Supplementary Table S3).

As the final step of the statistical analysis, the prevalence of respiratory and gastrointestinal disorders and CNS symptom group cases were compared between the general population and control group of 1000 dogs admitted to University Hospital in 2019. In the control group, the medical history of four animals did not contain enough data for their classification, so they were excluded from further analysis. In 2020 number of cases that fall into the CNS symptom group more than doubled compared to 2019 ($n = 1948$, $OR = 2.03$ 95% CI 1.3 - 3.17, $p = 0.001$, $RR = 1.97$ 95% CI 1.29 - 3.02, $p = 0.001$) (Figure 2.).




Figure 2. Prevalence of specific diagnosis at dogs admitted to the Veterinary Teaching Hospital in 2019 and 2020. Other diagnoses are not shown in this figure. Error bars represent a 95% confidence interval. AGI – acute gastrointestinal disorders, AR – acute respiratory disorders, CGI – chronic gastrointestinal disorders, CR – chronic respiratory disorders, CNS – central nervous system disorders.

4. Discussion

The results of this study were heavily dependent on the accuracy of the used serological assays. The previously described specificity of the neutralisation test [6,14,15] was confirmed. To ensure high specificity of ELISA, recombinant purified RBD was used as antigen and corrected OD was calculated. According to available data, this provides higher specificity of the ELISA method in detecting SARS-CoV-2 antibodies [15,16]. The ELISA specificity in the presented study was 100%. There was a discrepancy between the number of ELISA positive samples that tested MNT positive in the general population and COVID-19 infected households. The same was already observed in previous studies [17,18], and there are several possible explanations. Experimental studies recorded a lower titre of neutralisation antibodies in dogs than in other species [4]. The difference in serological reactivity is further confirmed by comparing serological testing results between dogs and human samples. In December 2020, 458 human serum samples were collected in Zagreb as a part of the general population serosurvey (data of the Croatian Institute of Public Health (TVC, IT)). Serological tests were done by the same research group as in this study, using the same methods in the same laboratory settings. In ELISA reactive samples, neutralising antibodies were detected in significantly fewer dogs than humans (Table 3.). The second possibility is that mild infections did not elicit the production of neutralising antibodies, as described in humans [19], or that sampling took place early into an infection or a long time after. The time of virus exposure for dogs in the general population was unknown, and seroprevalence shows a cumulative number of cases. On

the other hand, almost all dogs from COVID-19 infected households were sampled within four months of the confirmed human case, so it is highly possible that neutralising antibody titre had declined to an undetectable level in dogs infected early into the pandemic. This conclusion is further corroborated by significantly more MNT positive dogs at the end of the study period, assumingly due to recent exposure.

Since the beginning of COVID-19 pandemics, SARS-CoV-2 natural infections among dogs were described as isolated cases [20]. Due to higher susceptibility to SARS-CoV-2 infection in experimental conditions and their role in the SARS-CoV epidemic back in 2003 [21], cats have been the focus of scientific interest [14,20,22,23]. Only when the first serology results of dogs living in COVID-19 infected households became available, it was clear that human-dog transmissions are far more common than initially thought [7,8,24]. With 43.9% of ELISA and 25.64% of MNT positive dogs in COVID-19 infected households, the results of this study are in line with the studies mentioned above. More importantly, the secondary attack rate for dogs in this study was not different from those recorded in humans [25,26]. Spillover of SARS-CoV-2 to dogs was also visible in high seroprevalence in the general population. In this study, 14.69% of dogs had evidence of SARS-CoV-2 infection, with almost one in five dogs testing ELISA positive at the end of the study period. Those numbers are much higher than those at the end of the first wave in Croatia and other countries [6,7,16]. The most recent serosurvey in France also recorded a high prevalence of ELISA positive dogs (11.1%) in Bouches-du-Rhône, the region with a high number of human cases [27]. Little is known about the dynamic of immune response to SARS-CoV infection in dogs. However, a remarkable increase in the number of MNT positive dogs in the last month of the study suggests recent exposure. The extent of SARS-CoV-2 spread among dogs during the second wave of the COVID-19 pandemic is illustrated when seroprevalence in this study is compared with the earlier mentioned Croatian serosurvey results in the human population. There was no significant difference in the prevalence of ELISA positive samples in the humans and dogs sampled at the same period (Table 3.).

Table 3. Seroprevalence among dogs and humans from Zagreb sampled in December 2020.

| | | ELISA ^a | | Seroprevalence % (95% CI ^b) | Statistical significance |
|------------------|----------|--------------------|-----------------|---|--|
| | | Positive (n) | Negative (n) | | |
| Dog | | 31 | 136 | 18.56 (12.97 – 25.3) | ELISA positivity rate dog/human n = 625 |
| MNT ^c | Positive | 16 | NT ^d | - | $\chi^2^e = 0.184$ df = 1 p = 0.667 |
| | Negative | 15 | NT ^d | - | |
| Human | | 94 | 364 | 20.52 (16.92-24.52) | MNT positive dog/human samples n = 125 |
| MNT ^c | Positive | 70 | NT ^d | - | $\chi^2^e = 4.658$ df = 1 p = 0.031* |
| | Negative | 24 | NT ^d | - | |

Note: Only ELISA positive samples were tested for neutralisation. Data were analysed using a chi-square test. ^aELISA – enzyme-linked immunoassay, ^bCI – confidence interval, ^cMNT – microneutralisation test, ^dNT – not tested, ^echi-square test value, * - statistically significant

In our study, male dogs in the general population were significantly at increased risk of testing ELISA positive. Increased seropositivity in male dogs was described earlier [7] but was not confirmed in the second study [8]. Both of those studies were conducted on a much smaller sample. Smaller sample and overrepresentation of female dogs are a possible explanation for why male sex was not a significant risk factor in infected households in this research. Many studies show higher COVID-19 susceptibility, severity, and fatality

in men [28,29], while others do not [30,31]. In human cases, behavioural and social factors influence the sex distribution of human cases [32]. There is no evidence of SARS-CoV-2 infection independently spreading in the dog population [20]. This study further confirms this observation since dogs in animal shelters were not at increased risk of infection. The difference in social behaviour is a less possible explanation for the observed difference in susceptibility in dogs. It is most probably a result of intrinsic factors described in the human population and animal models [33-35]. In line with this conclusion is the age distribution of ELISA positive dogs in the general population. Male dogs at reproductive age [36] were significantly more often tested positive than males of any other age or females.

Age was a risk factor in COVID-19 positive households, with a ratio of ELISA positive dogs increasing with age. In the general population, observed seroprevalence was lowest in dogs less than one year but did not increase with age. Interestingly, the similar age distribution of COVID-19 cases has been observed in the human population [37-39]. It has been suggested that a lower number of recorded cases in children could result from lower susceptibility to SARS-CoV-2 infection, milder symptoms of disease or a combination of both [40]. As for sex, in the human population, an age-dependent pattern of SARS-CoV-2 cases may be influenced by extrinsic factors [41]. Well established pathogen, CCoV, has high seroprevalence in the dog population, and there is no difference between age groups [42]. The lower seroprevalence in dogs under the one-year age was described in CRCoV, another betacoronavirus of dogs [43]. The same is true for infections of young horses with equine coronavirus, newly described betacoronavirus [44] but, it is still to be concluded if this age susceptibility is maybe group specific for betacoronaviruses.

Finally, the breed was a significant risk factor, and Belgian shepherd dogs had 3.19 times increased risk of being seropositive. A major limitation of any study addressing breed predisposition is their number. In this study, breeds were further grouped based on their phylogenetic relationship [13]. Still, some clades here were represented by few animals or only one breed. Continental Herders were represented by Belgian shepherd dogs but were still only breed clade at increased risk of being infected. Genetic susceptibility in human cases is drawing much attention [45,46], and the molecular basis of different susceptibility recorded in dogs could give essential answers.

When the COVID-19 pandemic began, symptoms in humans have been suggesting primary respiratory infection, often progressing to pneumonia [1]. With the global spread, it became clear that a substantial number of cases are asymptomatic, or symptoms of other organ system involvement can develop [47]. COVID-19 is now recognised as a multi-system disease with a broad spectrum of clinical manifestations [48]. Dog owners from COVID-19 positive households did not notice significant health issues in their pets. It supports the conclusion that the acute phase of infections in dogs is primarily asymptomatic or mild in their course. There is growing evidence of the long-lasting effects of COVID-19 on human health, even in mild cases. The persistent impact of infection on dog health could not be fully addressed in animals from COVID-19 infected households. Only one animal was sampled more than four months after the assumed infection. Among dogs admitted to the University Hospital, seropositive animals were not at increased risk of respiratory disease or gastroenteritis, as expected based on human or cat infections [49-53].

Contrary to the recent study [54], clinical signs of heart disease were not correlated with serological status. Noticeably, seropositive dogs were almost at double the risk of developing CNS symptoms. This observation was further supported because, while the prevalence of respiratory and gastrointestinal disorders did not increase in 2020 compared to 2019, CNS disorder prevalence doubled. There is substantial evidence that neural tissue sustains viral replication leading to destruction and altered function [55,56]. Mild-nonspe-

cific neurologic symptoms are observed in human cases [57] that are not clinically assessable in dogs. More severe presentations such as impaired consciousness, acute stroke, seizures, encephalopathy, and meningoencephalitis reported in humans [58,59] are the possible cause of clinical presentation in seropositive dogs presented here since those symptoms can be readily recognised.

5. Conclusions

This study provides strong evidence that the incidence of SARS-CoV infections among dogs is not different from incidence in the human population. What is even more worrisome is the strong possibility that they are not just being infected, but infection affects their health. Future studies should determine the extent of this effect and risk factors and behaviour that could be influenced to protect dog health without influencing other welfare aspects. At the moment, there is no indication that dogs have a major, if any, role in the epidemiology of human infections and virus circulation is spread by human to human transmission. Still, recent evidence of infections in pet animals with new SARS-CoV-2 variants [54] raises the possibility that a new virus variant could emerge in dogs as well. This study advocates for an integrated approach to surveillance and control of the COVID-19 pandemic.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1. SARS-CoV-2 ELISA (enzyme-linked immunoassay) and MNT (microneutralisation test) result in different age groups among dogs living in COVID-19 positive households, Table S2. Breed predisposition to SARS-CoV-2 infection, Table S3. The interaction between age and CNS symptoms in the logistic regression model, Figure S1. Age and sex distribution of SARS-CoV-2 ELISA positive dogs.

Author Contributions: Vi. S., I. T. VC., L. B. conceptualised and designed the study. Vi. S. S.K., and Z.H. developed and carried out ELISA and microneutralisation test. Vi. S., I. B., S. Kovac collected animal serum samples, developed and carried out ELISA assay for dog serum samples. Vi. S., I. B., I. S., G. M., S. H., L. R., V. P., B. S., Z. V., M. B., M. C., J. H., K. M., I. Z., G. J., I. F., Z. S., M. P., collected serum samples and analysed collected medical records. M. M. M., G. M. and I. B. statistically analysed collected data. Vi. S. helped fund study. Vi. S. wrote the manuscript. All authors have read and agreed to the submitted version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved by Ethics Committee of Faculty of Veterinary Medicine, University of Zagreb (decision number: 640-01/20-02/12, 18 December 2020).

Informed Consent Statement: Not applicable

Data Availability Statement: The authors declare that the data supporting the findings of this study are available within the article and its Supplementary Information files, or are available from the authors upon reasonable request. Source data are available at 10.6084/m9.figshare.14602902.

Acknowledgments: We are grateful to Josko Mise for reviewing the final manuscript and Ljiljana Zmak for all the help during the work in biosecurity level 3 laboratory. The authors would like to show gratitude to International Atomic Energy Agency for the donation of the laboratory equipment that was used in this study. We are grateful to all owners that have participated in this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **2020**, *579*, 270-273, doi: <https://doi.org/10.1038/s41586-020-2012-7>.
2. Schlottau, K.; Rissmann, M.; Graaf, A.; Schön, J.; Sehl, J.; Wylezich, C.; Höper, D.; Mettenleiter, T.C.; Balkema-Buschmann, A.; Harder, T.; et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. *Lancet Microbe* **2020**, *1*, 218-225, doi: [https://doi.org/10.1016/S2666-5247\(20\)30089-6](https://doi.org/10.1016/S2666-5247(20)30089-6).

3. Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science* **2020**, *368*, 1016–1020, doi: <https://doi.org/10.1126/science.abb7015>.
4. Bosco-Lauth, A.M.; Hartwig, A.E.; Porter, S.M.; Gordy, P.W.; Nehring, M.; Byas, A.D.; VandeWoude, S.; Ragan, I.K.; Maison, R.M.; Bowen, R.A. Experimental infection of domestic dogs and cats with SARS-CoV-2: pathogenesis, transmission, and response to reexposure in cats. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 26382–26388, doi: <https://doi.org/10.1073/pnas.2013102117>.
5. Sit, T.H.; Brackman C.J.; Ip, S.M.; Tam, K.W.; Law, P.Y.; To, E.M.; Veronica, Y.T.; Sims, L.D.; Tsang, D.N.; Chu, D.K.; et al. Infection of dogs with SARS-CoV-2. *Nature* **2020**, *586*, 776–778, doi: <https://doi.org/10.1038/s41586-020-2334-5>.
6. Stevanovic, V.; Vilibic-Cavlek, T.; Tabain, I.; Benveniste, I.; Kovac, S.; Hruskar, Z.; Mauric, M.; Milasincic, L.; Antolasic, L.; Skrinjaric, A.; et al. Seroprevalence of SARS-CoV-2 infection among pet animals in Croatia and potential public health impact. *Transbound. Emerg. Dis.* **2020**, *00*, 1–7 doi: <https://doi.org/10.1111/tbed.13924>.
7. Patterson, E.I.; Elia, G.; Grassi, A.; Giordano, A.; Desario, C.; Medardo, M.; Smith, S.L.; Anderson, E.R.; Prince, T.; Patterson, G.T. et al. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. *Nat. Commun.* **2020**, *11*, 1–5, doi: <https://doi.org/10.1038/s41467-020-20097-0>.
8. Fritz, M.; Rosolen, B.; Krafft, E.; Becquart, P.; Elguero, E.; Vratskikh, O.; Denolly, S.; Boson, B.; Vanhomwegen, J.; Gouilh, M.A.; et al. High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households. *One Health* **2021**, *11*, 100192, doi: <https://doi.org/10.1016/j.onehlt.2020.100192>.
9. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. *Nat. Med.* **2021**, *27*, 601–615, doi: <https://doi.org/10.1038/s41591-021-01283-z>.
10. Moritz C.P.; Tholance Y.; Lassablière F.; Camdessanché J.P.; Antoine J.C. Reducing the risk of misdiagnosis of indirect ELISA by normalizing serum-specific background noise: the example of detecting anti-FGFR3 autoantibodies. *J. Immunol. Methods* **2019**, *466*, 52–56, doi: <https://doi.org/10.1016/j.jim.2019.01.004>.
11. Parker, H.G.; Dreger, D.L.; Rimbault, M.; Davis, B.W.; Mullen, A.B.; Carpintero-Ramirez, G.; Ostrander, E.A. Genomic analyses reveal the influence of geographic origin, migration, and hybridisation on modern dog breed development. *Cell. Rep.* **2017**, *19*, 697–708, doi: <https://doi.org/10.1016/j.celrep.2017.03.079>.
12. O'Neill, D.G.; Jackson, C.; Guy, J.H.; Church, D.B.; McGreevy, P.D.; Thomson, P.C.; Brodbelt, D.C. Epidemiological associations between brachycephaly and upper respiratory tract disorders in dogs attending veterinary practices in England. *Canine Genet. Epidemiol.* **2015**, *2*, 10 doi: <https://doi.org/10.1186/s40575-015-0023-8>.
13. Packer, R.M.A.; Hendricks, A.; Tivers, M.S.; Burn, C.C. Impact of facial conformation on canine health: brachycephalic obstructive airway syndrome. *PLoS ONE* **2015**, *10*, 0137496, doi: <https://doi.org/10.1371/journal.pone.0137496>.
14. Zhang, Q.; Zhang, H.; Gao, J.; Huang, K.; Yang, Y.; Hui, X.; He, X.; Li, C.; Gong, W.; Zhang, Y.; et al. A serological survey of SARS-CoV-2 in cat in Wuhan. *Emerg. Microbes Infect.* **2020**, *9*, 2013–2019, doi: <https://doi.org/10.1080/22221751.2020.1817796>.
15. Perera, R.A.; Mok, C.K.; Tsang, O.T.; Lv, H.; Ko, R.L.; Wu, N.C.; Yuan, M.; Leung, W.S.; Chan, J.M.; Chik, T.S.; et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Euro Surveill.* **2020**, *25*, 2000421, doi: <https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421>.
16. Zhao, S.; Schuurman, N.; Li, W.; Wang, C.; Smit, L.A.; Broens, E.M.; Wagenaar, J.A.; van Kuppeveld, F.J.; Bosch, B.J.; Egberink, H.; et al. Serologic screening of severe acute respiratory syndrome coronavirus 2 infection in cats and dogs during first coronavirus disease wave, the Netherlands. *Emerg. Infect. Dis.* **2021**, *27*, 1362–1370, doi: <https://doi.org/10.3201/eid2705.204055>.
17. Robbiani, D.F.; Gaebler, C.; Muecksch, F.; Lorenzi, J.C.; Wang, Z.; Cho, A.; Agudelo, M.; Barnes, C.O.; Gazumyan, A.; Finklin, S.; et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **2020**, *584*, 437–442, doi: <https://doi.org/10.1038/s41586-020-2456-9>.
18. Suthar, M.S.; Zimmerman, M.G.; Kauffman, R.C.; Mantus, G.; Linderman, S.L.; Hudson, W.H.; Vanderheiden, A.; Nyhoff, L.; Davis, C.W.; Adekunle, O.; et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell. Rep. Med.* **2020**, *1*, 100040, doi: <https://doi.org/10.1016/j.xcrm.2020.100040>.
19. Okba, N.M.; Müller, M.A.; Li, W.; Wang, C.; GeurtsvanKessel, C.H.; Corman, V.M.; Lamers, M.M.; Sikkema, R.S.; de Bruin, E.; Chandler, F.D.; et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. *Emerg. Infect. Dis.* **2020**, *26*, 1478–1488, doi: <https://doi.org/10.3201/eid2607.200841>.
20. Decaro, N.; Balboni, A.; Bertolotti, L.; Martino, P.A.; Mazzei, M.; Mira, F.; Pagnini, U. SARS-CoV-2 infection in dogs and cats: facts and speculations. *Front. Vet. Sci.* **2021**, *8*, 80, doi: <https://doi.org/10.3389/fvets.2021.619207>.
21. Martina, B.E.; Haagmans, B.L.; Kuiken, T.; Fouchier, R.A.; Rimmelzwaan, G.F.; Van Amerongen, G.; Peiris, J.M.; Lim, W.; Osterhaus, A.D. Virology: SARS virus infection of cats and ferrets. *Nature* **2003**, *425*, 915, doi: <https://doi.org/10.1038/425915a>.
22. Michelitsch, A.; Hoffmann, D.; Wernike, K.; Beer, M. Occurrence of antibodies against SARS-CoV-2 in the domestic cat population of Germany. *Vaccines* **2020**, *8*, 772, doi: <https://doi.org/10.3390/vaccines8040772>.
23. Li, X. Cats under the shadow of the SARS-CoV-2 pandemic. *Transbound. Emerg. Dis.* **2020**, *67*, 1416–1417, doi: <https://doi.org/10.1111/tbed.13599>.
24. Hamer, S.A.; Pauvolid-Corrêa, A.; Zecca, I.B.; Davila, E.; Auckland, L.D.; Roundy, C.M.; Tang, W.; Torchetti, M.; Killian, M.L.; Jenkins-Moore, M.; et al. Natural SARS-CoV-2 infections, including virus isolation, among serially tested cats and dogs in households with confirmed human COVID-19 cases in Texas, USA. *bioRxiv*, **2020**. Available online: <https://doi.org/10.1101/2020.12.08.416339> (accessed on 1 June 2021).

25. Grijalva, C.G.; Rolfes, M.A.; Zhu, Y.; McLean, H.Q.; Hanson, K.E.; Belongia, E.A.; Halasa, N.B.; Kim, A.; Reed, C.; Fry, A.M.; et al. Transmission of SARS-CoV-2 infections in households—Tennessee and Wisconsin, April–September 2020. *Morb. Mortal. Wkly. Rep.* **2020**, *69*, 1631, doi: <https://doi.org/10.15585/mmwr.mm6944e1>.
26. Yi, B.; Fen, G.; Cao, D.; Cai, Y.; Qian, L.; Li, W.; Wen, Z.; Sun, X. Epidemiological and clinical characteristics of 214 families with COVID-19 in Wuhan, China. *Int. J. Infect. Dis.* **2021**, *105*, 113–119, doi: <https://doi.org/10.1016/j.ijid.2021.02.021>.
27. Laidoudi, Y.; Sereme, Y.; Medkour, H.; Watier-Grillot, S.; Scandola, P.; Ginesta, J.; Andréof, V.; Labarde, C.; Comtet, L.; Pourquier, P.; et al. SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay. *Méditerranée Infection*, 2021. Available online: <https://doi.org/10.35088/tgt4-r649> (accessed on 1 June 2021).
28. Abate, B.B.; Kassie, A.M.; Kassaw, M.W.; Aragie, T.G.; Masresha, S.A. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. *BMJ Open* **2020**, *10*, 040129, doi: <http://dx.doi.org/10.1136/bmjopen-2020-040129>.
29. Stall, N.M.; Wu, W.; Lapointe-Shaw, L.; Fisman, D.N.; Giannakeas, V.; Hillmer, M.P.; Rochon, P.A. Sex-specific differences in COVID-19 testing, cases and outcomes: a population-wide study in Ontario, Canada. *J. Am. Geriatr. Soc.* **2020**, *68*, 2188–2191, doi: <https://doi.org/10.1111/jgs.16761>.
30. Gargaglioni, L.H.; Marques, D.A. Let's talk about sex in the context of COVID-19. *J. Appl. Physiol.* **2020**, *128*, 1533–1538, doi: <https://doi.org/10.1152/japplphysiol.00335.2020>.
31. Peckham, H.; de Gruijter, N.M.; Raine, C.; Radziszewska, A.; Ciurtin, C.; Wedderburn, L.R.; Rosser, E.C.; Webb, K.; Deakin, C.T. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ICU admission. *Nat. Commun.* **2020**, *11*, 1–10, doi: <https://doi.org/10.1038/s41467-020-19741-6>.
32. Li, A.J.; Li, X. Sex-dependent immune response and lethality of COVID-19. *Stem Cell Res.* **2021**, *50*, 102116, doi: <https://doi.org/10.1016/j.scr.2020.102116>.
33. Ahmed, S.A.; Talal, N. Sex hormones and the immune system--Part 2. Animal data. *Baillieres Clin. Rheumatol.* **1990**, *4*, 13–31, doi: [https://doi.org/10.1016/S0950-3579\(05\)80241-9](https://doi.org/10.1016/S0950-3579(05)80241-9).
34. Kissick, H.T.; Sanda, M.G.; Dunn, L.K.; Pellegrini, K.L.; On, S.T.; Noel, J.K.; Arredouani, M.S. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 9887–9892, doi: <https://doi.org/10.1073/pnas.1402468111>.
35. Arredouani, M.S. New insights into androgenic immune regulation. *Oncoimmunology* **2014**, *3*, 954968, doi: <https://doi.org/10.4161/21624011.2014.954968>.
36. Wallis, L.J.; Range, F.; Müller, C.A.; Serisier, S.; Huber, L.; Virányi, Z. Lifespan development of attentiveness in domestic dogs: drawing parallels with humans. *Front. Psychol.* **2014**, *5*, 71, doi: <https://doi.org/10.3389/fpsyg.2014.00071>.
37. Cereda, D.; Tirani, M.; Rovida, F.; Demicheli, V.; Ajelli, M.; Poletti, P.; Trentini, F.; Guzzetta, G.; Marziano, V.; Barone, A.; et al. The early phase of the COVID-19 outbreak in Lombardy, Italy. *arXiv*. 2020. Available online: <https://arxiv.org/abs/2003.09320> (accessed on 1 June 2021).
38. Shim, E.; Tariq, A.; Choi, W.; Lee, Y.; Chowell, G. Transmission potential and severity of COVID-19 in South Korea. *Int. J. Infect. Dis.* **2020**, *93*, 339–344, doi: <https://doi.org/10.1016/j.ijid.2020.03.031>.
39. Sun, K.; Chen, J.; Viboud, C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. *Lancet Digit. Health* **2020**, *2*, 201–208, doi: [https://doi.org/10.1016/S2589-7500\(20\)30026-1](https://doi.org/10.1016/S2589-7500(20)30026-1).
40. Davies, N.G.; Klepac, P.; Liu, Y.; Prem, K.; Jit, M.; Eggo, R.M. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat. Med.* **2020**, *26*, 1205–1211, doi: <https://doi.org/10.1038/s41591-020-0962-9>.
41. Mossong, J.; Hens, N.; Jit, M.; Beutels, P.; Auranen, K.; Mikolajczyk, R.; Massari, M.; Salmaso, S.; Tomba, G.S.; Wallinga, J.; et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLoS Med.* **2008**, *5*, 74, doi: <https://doi.org/10.1371/journal.pmed.0050074>.
42. Tennant, B.J.; Gaskell, R.M.; Jones, R.C.; Gaskell, C.J. Studies on the epizootiology of canine coronavirus. *Vet. Rec.* **1993**, *132*, 7–11, doi: <https://doi.org/10.1136/vr.132.1.7>.
43. Priestnall, S.L.; Brownlie, J.; Dubovi, E.J.; Erles, K. Serological prevalence of canine respiratory coronavirus. *Vet. Microbiol.* **2006**, *115*, 43–53, doi: <https://doi.org/10.1016/j.vetmic.2006.02.008>.
44. Pusterla, N.; Vin, R.; Leutenegger, C.; Mittel, L.D.; Divers, T.J. Equine coronavirus: An emerging enteric virus of adult horses. *Equine Vet. Educ.* **2016**, *28*, 216–223, doi: <https://doi.org/10.1111/eve.12453>.
45. Hussain, M.; Jabeen, N.; Raza, F.; Shabbir, S.; Baig, A.A.; Amanullah, A.; Aziz, B. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. *J. Med. Virol.* **2020**, *92*, 1580–1586, doi: <https://doi.org/10.1002/jmv.25832>.
46. Cao, Y.; Li, L.; Feng, Z.; Wan, S.; Huang, P.; Sun, X.; Wen, F.; Huang, X.; Ning, G.; Wang, W. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov.* **2020**, *6*, 11, doi: <https://doi.org/10.1038/s41421-020-0147-1>.
47. Oran, D.P.; Topol, E.J. The proportion of SARS-CoV-2 infections that are asymptomatic : a systematic Review. *Ann. Intern. Med.* **2020**, *173*, 362–367, doi: <https://doi.org/10.7326/M20-3012>.
48. Gupta, A.; Madhavan, M.V.; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T.S.; Bickdeli, B.; Ahluwalia, N.; Ausiello, J.C.; Wan, E.Y.; et al. Extrapulmonary manifestations of COVID-19. *Nat. Med.* **2020**, *26*, 1017–1032, doi: <https://doi.org/10.1038/s41591-020-0968-3>.
49. Carfi, A.; Bernabei, R.; Landi, F. Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. *J. Am. Med. Assoc.* **2021**, *324*, 603–605, doi: <https://doi.org/10.1001/jama.2020.12603>.

50. Chopra, V.; Flanders, S.A.; O'Malley, M.; Malani, A.N.; Prescott, H.C. Sixty-day outcomes among patients hospitalised with COVID-19. *Ann. Intern. Med.* **2020**, doi: <https://doi.org/10.7326/M20-5661>.
51. Garrigues, E.; Janvier, P.; Kherabi, Y.; Le Bot, A.; Hamon, A.; Gouze, H.; Doucet, L.; Berkani, S.; Olios, E.; Mallart, E.; et al. Post-discharge persistent symptoms and health-related quality of life after hospitalisation for COVID-19. *J. Infect.* **2020**, *81*, 4–6, doi: <https://doi.org/10.1016/j.jinf.2020.08.029>.
52. Hosie, M.J.; Epifano, I.; Herder, V.; Orton, R.; Stevenson, A.; Johnson, N.; MacDonald, E.; Dunbar, D.; McDonald, M.; Howie, F.; et al. Respiratory disease in cats associated with human-to-cat transmission of SARS-CoV-2 in the UK. *bioRxiv* **2020**. Available online: <https://doi.org/10.1101/2020.09.23.309948> (accessed on 1 June 2021).
53. Garigliany, M.; Van Laere, A.S.; Clercx, C.; Giet, D.; Escriou, N.; Huon, C.; Van Der Werf, S.; Eloit, M.; Desmecht, D. SARS-CoV-2 natural transmission from human to cat, Belgium, March 2020. *Emerg. Infect. Dis.* **2020**, *26*, 3069, doi: <https://doi.org/10.3201/eid2612.202223>.
54. Ferasin, L.; Fritz, M.; Ferasin, H.; Becquart, P.; Legros, V.; Leroy, E.M. Myocarditis in naturally infected pets with the British variant of COVID-19. *bioRxiv*. **2021**. Available online: <https://doi.org/10.1101/2021.03.18.435945> (accessed on 1 June 2021).
55. Moriguchi, T.; Harii, N.; Goto, J.; Harada, D.; Sugawara, H.; Takamino, J.; Ueno, M.; Sakata, H.; Kondo, K.; Myose, N.; et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int. J. Infect. Dis.* **2020**, *94*, 55–58, doi: <https://doi.org/10.1016/j.ijid.2020.03.062>.
56. Domingues, R.B.; Mendes-Correa, M.C.; de Moura Leite, F.B.V.; Sabino, E.C.; Salarini, D.Z.; Claro, I.; Santos D.W.; de Jesus, J.G.; Ferreira, N.E.; Romano, C.M.; et al. First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. *J. Neurol.* **2020**, *267*, 3154–3156, doi: <https://doi.org/10.1007/s00415-020-09996-w>.
57. Pezzini, A.; Padovani, A. Lifting the mask on neurological manifestations of COVID-19. *Nat. Rev. Neurol.* **2020**, *16*, 636–644, doi: <https://doi.org/10.1038/s41582-020-0398-3>.
58. Ellul, M.A.; Benjamin, L.; Singh, B.; Lant, S.; Michael, B.D.; Easton, A.; Kneen, R.; Defres, S.; Sejvar, J.; Solomon, T. Neurological associations of COVID-19. *Lancet Neurol.* **2020**, *19*, 767–783, doi: [https://doi.org/10.1016/S1474-4422\(20\)30221-0](https://doi.org/10.1016/S1474-4422(20)30221-0).
59. Nersesjan, V.; Amiri, M.; Lebech, A.M.; Roed, C.; Mens, H.; Russell, L.; Fonsmark, L.; Berntsen, M.; Sigurdsson, S.T.; Carlsen, J.; et al. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. *J. Neurol.* **2021**, *1–19*, doi: <https://doi.org/10.1007/s00415-020-10380-x>.